High-doses of proton pump inhibitors in refractory gastro-intestinal cancer

A case series and the state of art

Rosa Falcone, Michela Roberto, Chiara D'Antonio, Adriana Romiti, Annalisa Milano, Concetta Elisa Onesti, Paolo Marchetti, Stefano Fais

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumour microenvironment acidification thus restoring chemotherapeutic sensitivity. Moreover, several clinical data supports the role of cytotoxic drugs at low-dose continuously delivered as anticancer therapy. Methods Clinical records of three patients affected with gastrointestinal cancer refractory to standard treatments, who had received a combination of high-dose rabeprazole and metronomic chemotherapy were reviewed. Results The first case, a 78-year-old man was treated for lung metastasis from colon adenocarcinoma. The second case, a 73-year-old man was treated for metastatic rectal cancer to the liver. The third one, a 68-year-old man, underwent the combination regimen for colon cancer with lung, liver and peritoneal metastases. Conclusions Despite the failure of previous standard chemotherapy for metastatic disease, good clinical outcome was shown in these patients treated with an unconventional association of high-dose PPIs and metronomic chemotherapy.

Original languageEnglish
Pages (from-to)1503-1505
Number of pages3
JournalDigestive and Liver Disease
Volume48
Issue number12
DOIs
Publication statusPublished - Dec 1 2016
Externally publishedYes

Fingerprint

Intestinal Neoplasms
Proton Pump Inhibitors
Drug Therapy
Rabeprazole
Neoplasm Metastasis
Gastrointestinal Neoplasms
Tumor Microenvironment
Liver Neoplasms
Rectal Neoplasms
Colonic Neoplasms
Lung Neoplasms
Colon
Adenocarcinoma
Lung
Liver
Therapeutics
Pharmaceutical Preparations

Keywords

  • Colorectal cancer
  • Metronomic chemotherapy
  • Proton-pump inhibitors
  • Refractory disease

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Falcone, R., Roberto, M., D'Antonio, C., Romiti, A., Milano, A., Onesti, C. E., ... Fais, S. (2016). High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. Digestive and Liver Disease, 48(12), 1503-1505. https://doi.org/10.1016/j.dld.2016.08.126

High-doses of proton pump inhibitors in refractory gastro-intestinal cancer : A case series and the state of art. / Falcone, Rosa; Roberto, Michela; D'Antonio, Chiara; Romiti, Adriana; Milano, Annalisa; Onesti, Concetta Elisa; Marchetti, Paolo; Fais, Stefano.

In: Digestive and Liver Disease, Vol. 48, No. 12, 01.12.2016, p. 1503-1505.

Research output: Contribution to journalArticle

Falcone, R, Roberto, M, D'Antonio, C, Romiti, A, Milano, A, Onesti, CE, Marchetti, P & Fais, S 2016, 'High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art', Digestive and Liver Disease, vol. 48, no. 12, pp. 1503-1505. https://doi.org/10.1016/j.dld.2016.08.126
Falcone, Rosa ; Roberto, Michela ; D'Antonio, Chiara ; Romiti, Adriana ; Milano, Annalisa ; Onesti, Concetta Elisa ; Marchetti, Paolo ; Fais, Stefano. / High-doses of proton pump inhibitors in refractory gastro-intestinal cancer : A case series and the state of art. In: Digestive and Liver Disease. 2016 ; Vol. 48, No. 12. pp. 1503-1505.
@article{d3bc66db294b481b8e5de8b952a97954,
title = "High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art",
abstract = "Background In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumour microenvironment acidification thus restoring chemotherapeutic sensitivity. Moreover, several clinical data supports the role of cytotoxic drugs at low-dose continuously delivered as anticancer therapy. Methods Clinical records of three patients affected with gastrointestinal cancer refractory to standard treatments, who had received a combination of high-dose rabeprazole and metronomic chemotherapy were reviewed. Results The first case, a 78-year-old man was treated for lung metastasis from colon adenocarcinoma. The second case, a 73-year-old man was treated for metastatic rectal cancer to the liver. The third one, a 68-year-old man, underwent the combination regimen for colon cancer with lung, liver and peritoneal metastases. Conclusions Despite the failure of previous standard chemotherapy for metastatic disease, good clinical outcome was shown in these patients treated with an unconventional association of high-dose PPIs and metronomic chemotherapy.",
keywords = "Colorectal cancer, Metronomic chemotherapy, Proton-pump inhibitors, Refractory disease",
author = "Rosa Falcone and Michela Roberto and Chiara D'Antonio and Adriana Romiti and Annalisa Milano and Onesti, {Concetta Elisa} and Paolo Marchetti and Stefano Fais",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.dld.2016.08.126",
language = "English",
volume = "48",
pages = "1503--1505",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "12",

}

TY - JOUR

T1 - High-doses of proton pump inhibitors in refractory gastro-intestinal cancer

T2 - A case series and the state of art

AU - Falcone, Rosa

AU - Roberto, Michela

AU - D'Antonio, Chiara

AU - Romiti, Adriana

AU - Milano, Annalisa

AU - Onesti, Concetta Elisa

AU - Marchetti, Paolo

AU - Fais, Stefano

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumour microenvironment acidification thus restoring chemotherapeutic sensitivity. Moreover, several clinical data supports the role of cytotoxic drugs at low-dose continuously delivered as anticancer therapy. Methods Clinical records of three patients affected with gastrointestinal cancer refractory to standard treatments, who had received a combination of high-dose rabeprazole and metronomic chemotherapy were reviewed. Results The first case, a 78-year-old man was treated for lung metastasis from colon adenocarcinoma. The second case, a 73-year-old man was treated for metastatic rectal cancer to the liver. The third one, a 68-year-old man, underwent the combination regimen for colon cancer with lung, liver and peritoneal metastases. Conclusions Despite the failure of previous standard chemotherapy for metastatic disease, good clinical outcome was shown in these patients treated with an unconventional association of high-dose PPIs and metronomic chemotherapy.

AB - Background In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumour microenvironment acidification thus restoring chemotherapeutic sensitivity. Moreover, several clinical data supports the role of cytotoxic drugs at low-dose continuously delivered as anticancer therapy. Methods Clinical records of three patients affected with gastrointestinal cancer refractory to standard treatments, who had received a combination of high-dose rabeprazole and metronomic chemotherapy were reviewed. Results The first case, a 78-year-old man was treated for lung metastasis from colon adenocarcinoma. The second case, a 73-year-old man was treated for metastatic rectal cancer to the liver. The third one, a 68-year-old man, underwent the combination regimen for colon cancer with lung, liver and peritoneal metastases. Conclusions Despite the failure of previous standard chemotherapy for metastatic disease, good clinical outcome was shown in these patients treated with an unconventional association of high-dose PPIs and metronomic chemotherapy.

KW - Colorectal cancer

KW - Metronomic chemotherapy

KW - Proton-pump inhibitors

KW - Refractory disease

UR - http://www.scopus.com/inward/record.url?scp=85006355923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006355923&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2016.08.126

DO - 10.1016/j.dld.2016.08.126

M3 - Article

VL - 48

SP - 1503

EP - 1505

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 12

ER -